189 related articles for article (PubMed ID: 34092162)
1. De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris - a systematic review.
McClatchy J; Yap T; Koo K; Kern JS; Scardamaglia L
Expert Opin Biol Ther; 2021 Dec; 21(12):1591-1601. PubMed ID: 34092162
[No Abstract] [Full Text] [Related]
2. [Treatment of severe refractory pemphigus vulgaris with rituximab].
Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
[TBL] [Abstract][Full Text] [Related]
3. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
Barrera MV; Mendiola MV; Bosch RJ; Herrera E
J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab induced remission of pemphigus vulgaris: 2 cases].
Borel C; Launay F; Garrouste C; Astudillo L; Bazex J; Arlet P; Paul C; Viraben R; Sailler L
Rev Med Interne; 2007 Apr; 28(4):266-8. PubMed ID: 17188405
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Pemphigus Vulgaris With Ofatumumab.
Rapp M; Pentland A; Richardson C
J Drugs Dermatol; 2018 Dec; 17(12):1338-1339. PubMed ID: 30586270
[TBL] [Abstract][Full Text] [Related]
7. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
10. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
12. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris.
Baum S; Raviv T; Gilboa S; Pavlotsky F; Barzilai A
Acta Derm Venereol; 2020 Oct; 100(17):adv00286. PubMed ID: 32985675
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Therapy for Childhood Pemphigus Vulgaris.
Kincaid L; Weinstein M
Pediatr Dermatol; 2016; 33(2):e61-4. PubMed ID: 26765543
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.
Salopek TG; Logsetty S; Tredget EE
J Am Acad Dermatol; 2002 Nov; 47(5):785-8. PubMed ID: 12399777
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
19. Delayed response of oral pemphigus vulgaris to rituximab treatment.
Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
[TBL] [Abstract][Full Text] [Related]
20. Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability.
Ciolfi C; Sernicola A; Alaibac M
Patient Prefer Adherence; 2022; 16():3035-3043. PubMed ID: 36387051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
